Houston Airport Systems launches app to improve accessibility

flight plan

The Access Houston Airports is optimized with tools for children with developmental disabilities to use during their travels in and out of Houston. Photo courtesy of the Houston Airport System

Houston's two airports have a new digital tool to help its passengers with developmental disabilities better navigate their journey in and out of town.

George Bush Intercontinental Airport and William P. Hobby Airport have partnered with Chicago-based Autism innovation company, Infiniteach, to launch the Access Houston Airports mobile app. The free technology provides tools to children with autism or other conditions — as well as their caregivers — throughout their Houston Airport System experience.

"Houston Airports continues to embrace technology to go the extra mile to assist passengers of all abilities on their journey through our airports," says Jesus Saenz, Houston Airports' COO, in a news release.

The Centers for Disease Control and Prevention estimates that 13 percent of the United states have an "invisible" developmental disability like autism. Tim Joniec, the director of government relations and Americans with Disability Act coordination at HAS, says in the release that this translates to 20,000 daily Houston travelers.

"Houston Airports is introducing this app to ease anxiety for these families and provide information and resources that will make their visit to the airport an engaging and meaningful experience," Joniec says in the release.

The app uses researched-based strategies and features, including guides, short picture stories, scheduling tool, checklist feature, as well as caregiver information like terminal maps and support.

The app launch is just one improvement HAS has made. The organization has also conducted employee disability awareness training, Aira technology for the blind or low vision, service dog familiarization training, and nonprofit involvement through Southwest Airlines and United Airlines' annual Wings for all event.

Users can set a schedule for themselves, which can give them some comfort as they travel and accomplish tasks. Courtesy of HAS

Houston First Corp. will sponsor the Aira technology at several venues across the city so that the blind and vision impaired can enjoy each area. Photo by Micahl Wycoff

Low-vision technology allow for the seeing impaired to have access to Houston venues

Eyes to see

A partnership between the Houston First Corporation and Aira, an app that helps blind and low-vision people gain independence by navigating tasks and public spaces, is now live at venues around the city.

Houston First will cover the costs of use for the app in its venues, including the George R. Brown Convention Center, Avenida Houston, Wortham Theater Center, and Jesse H. Jones Hall for the Performing Arts. The organization has plans to expand to the Miller Outdoor Theatre, said John Gonzalez, senior vice president of operations and general manager for Houston First.

"Technology is changing the experiences users have at our events," Gonzalez said. "We want to make our venues as accessible as possible."

California-based Aira's role in offering a vessel for facilities to be more accessible to low-vision and blind Houstonians is groundbreaking, said Vince Morvillo, an account executive with Aira who is blind.

"This technology is as important to a blind person as it is to a sighted person," Morvillo said. "You, as a person with sight, have the opportunity to look, to see things, to interact with people. When you're blind, you're not out and about; you don't have too many people to interact with. The ability to be able to go and do something when you choose to do so is really important."

The app essentially creates sight on demand. Users can use the Aira app on their smartphones and be connected to a trained operator, who will help them navigate the scene around them using video being fed to the app through their phone. The operators will then guide the user to their destination or even help them with everyday necessities like grocery shopping.

"The blind world needs this," Morvillo said. "This technology gets blind people out in the world. Businesses know how successful they are by how many people support them. I just don't understand why blind people are an untapped resource. Nobody's out there trying to get the blind shopper."

In addition to the blind population, Morvillo says that this will also help the aging population, who may often struggle with their vision later in life, and will increase accessibility options around the city.

Aira and Houston First's efforts to increase accessibility for patrons are now being recognized nationally. The National Federation of the Blind recently announced it would be bringing its annual convention to Houston in 2020.

"We are thrilled to host the group and are committed to providing a safe and enjoyable experience for all visitors," Houston First said in an email to InnovationMap. "It is our goal that Houston First venues provide an entertaining and immersive experience for all guests, and our partnership with Aira puts us one step closer to achieving that goal."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings